BIAF - צמיחת הכנסות שנתית ב-12 החודשים האחרונים bioaffinitytech.com

The scalability of lung cancer diagnostics reduces costs through test standardization. The annual sales revenue trend over four quarters on the GURU.Markets chart demonstrates a trajectory where the -18.60 mark serves as a key metric. The success of bioAffinity Technologies (BIAF) is driven by cytometry experts who developed the high-precision non-invasive CyPath Lung sputum analysis for preventive oncology.

For bioAffinity Technologies (BIAF), which integrates ESG standards into molecular diagnostics, this metric reflects the commercialization efficiency of eco-friendly digital solutions by calculating the rolling twelve-month revenue change. By analyzing the Last Twelve Months (LTM) trading revenue growth, an investor eliminates seasonality and assesses the actual scaling dynamics of the business, enabling the timely detection of stagnation and confirming the sustainability of the company's financial model.